MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Clinic vs Self-Referral for a Home-Based Fracture Prevention Trial of Zoledronate vs Placebo in Patients with Neurodegenerative Parkinsonism

    C. Tanner, N. Luthra, S. Goldman, R. Zuzuarregui, E. Brown, C. Meng, J. Perkins, T. Hue, C. Schambach, D. Kreisel, D. Young, I. Bledsoe, L. Racelo, P. Nanda Kumar, P. Ranola, M. Schwarzschild, R. Dorsey, A. Espay, S. Krischer, J. Falcon, C. Comella, M. Siddiqui, F. Gao, M. Ledoux, E. Byrd, I. Litvan, N. Mcfarland, K. Mitchell, D. Standaert, J. Beck, K. Williams, M. Drake, D. Bauer, K. Lyles, S. Cummings (SAN FRANCISCO, USA)

    Objective: To evaluate recruitment, eligibility and characteristics of clinic referred vs self-referred patients in the ongoing Trial of Parkinson’s and Zoledronate (TOPAZ, NCT03924414) Background: People…
  • 2024 International Congress

    Predictability of Motor States With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease

    R. Hauser, M. Bouchard, D. Santos-Garcia, L. Bergmann, R. Gupta, L. Harmer, M. Shah, C. Yan, S. Isaacson (Tampa, USA)

    Objective: To assess predictability of “On” or “Off” motor states in patients (pts) with advanced Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDp/CDp). Background: Pts with…
  • 2024 International Congress

    Lithium Therapy Associated with Reductions in Serum Neurofilament Light Chain (NfL) in Parkinson’s Disease.

    T. Guttuso, JR., R. Shepherd (Williamsville, USA)

    Objective: To assess the effects of lithium aspartate and lithium carbonate therapy for 24 weeks on serum NfL in Parkinson’s disease (PD). Background: Lithium has…
  • 2024 International Congress

    Boosting Clinical Trial Power in Parkinson’s Disease with AI-Generated Digital Twins

    C. Murray, C. Kusiak, A. Vanderbeek, D. Bertolini, E. Tramel (San Francisco, USA)

    Objective: To evaluate the incorporation of prognostic digital twins to enhance traditional clinical trials in Parkinson’s Disease (PD) for disease modifying therapies. We assess the…
  • 2024 International Congress

    Advancing regulatory endorsed drug development tools in alignment with emerging biology: The Critical Path for Parkinson’s Consortium

    D. Stephenson, C. Kopil, M. Müller, O. Mabrouk, H. Kocherla, R. Comley, K. Yee, T. Dam, G. Pagano, J. Seibyl, K. Marek, T. Simuni (Tucson, USA)

    Objective: To advance the regulatory maturity of drug development tools to support the newly proposed integrated staging of Neuronal Synuclein Disease (NSD-ISS) with focus on…
  • 2024 International Congress

    Non-interventional phase 0 study for the collection of biospecimens from patients with Parkinson’s Disease (PD) to support the development of a diagnostic classifier for LRRK2-driven PD

    L. Desnoyers, S. Dheerendra, C. Wong, T. Dang, S. Esmaeeli, M. van Derbrug, M. Nalls, A. Ellenbogen, S. Jackson (South San Francisco, USA)

    Objective: Measure LRRK2 pathway activity in Parkinson’s Disease patients stratified using a genetic predictive classifier model. Background: Extensive research has shown that overactivation of the…
  • 2024 International Congress

    Unraveling Plantar Pressure Dynamics in Parkinson’s Disease with Freezing of Gait: Taking Steps through Its Characters and Predictive Factors

    T. Tiraweerakhajorn, W. Phuenpathom, P. Panyakaew, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To elucidate plantar pressure characteristics in different stages of PD patients who experienced FOG and identify predictive factors for alterations in plantar pressure parameters.…
  • 2024 International Congress

    Comparison of olfactory testing and PSG for detection of alpha-synuclein pathology in patients with dream enactment behavior or REM sleep behavior disorder

    E. Brown, L. Chahine, A. Siderowf, C. Gochanour, C. Caspell-Garcia, M. Brumm, M. Marshall, C. Stanley, C. Soto, L. Concha, T. Sherer, T. Tanner, T. Simuni, K. Marek (San Francisco, USA)

    Objective: To compare the proportion of people with abnormal alpha-synuclein among groups with differing levels of certainty of REM sleep behavior disorder (RBD). Background: REM…
  • 2024 International Congress

    LRRK2 inhibition by BIIB122/DNL151 in participants with Pathogenic LRRK2 Variants and Parkinson’s disease: Study Design to Evaluate Safety, Pharmacodynamics and Pharmacokinetics

    D. Jennings, S. Huntwork-Rodriguez, J. Kluss, S. Ota, S. Dhuria, R. Maciuca, K. Fraser, B. Hersh, Z. Berger, C. Ho, P. Chin (South San Francisco, USA)

    Objective: To evaluate safety and biomarker effects of BIIB122/DNL151 in participants with pathogenic LRRK2 variants diagnosed with Parkinson’s disease (LRRK2-PD). Background: Increased LRRK2 kinase activity…
  • 2024 International Congress

    Treatment Patterns With Long-Term Foslevodopa/Foscarbidopa Use in Parkinson’s Disease

    J. Aldred, T. Henriksen, M. Bouchard, J. Martínez-Castrillo, M. Soileau, D. Standaert, L. Bergmann, R. Gupta, P. Kukreja, M. Shah, S. Isaacson (Spokane, USA)

    Objective: To assess long-term treatment switch patterns and discontinuation rates in patients (pts) with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDp/CDp) mono- or combination therapy.…
  • « Previous Page
  • 1
  • …
  • 405
  • 406
  • 407
  • 408
  • 409
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley